Tentiation of the anti-tumor effect of actinomycin D by tumor necrosis factor α in mice: Correlation between in vitro and in vivo results

International Journal of Cancer

Volumn 66, Issue 3, 1996, Pages 374-379

  Lasek, Witold ^a   Giermasz, Adam ^a   Kuc, Katarzyna ^a   Wańkowicz, Anna ^a   Feleszko, Wojciech ^a   Goła̧b, Jakub ^a   Zagozdzon, Radosław ^a   Stokłosa, Tomasz ^a   Jakóbisiak, Marek ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

DACTINOMYCIN; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG POTENTIATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL LINE;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CELL LINE; DACTINOMYCIN; DRUG SYNERGISM; LEUKEMIA L1210; LUNG NEOPLASMS; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, INBRED DBA; NEOPLASMS, EXPERIMENTAL; SARCOMA, EXPERIMENTAL; TIME FACTORS; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0029900289     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1097-0215(19960503)66:3<374::aid-ijc18>3.0.co;2-b     Document Type: Article

References (25)

1. EXANDER, R.B., ISAACS, J.T. and COFFEY, D.S., Tumor necrosis factor enhances the in vitro and in vivo efficacy of chemotherapeutic drugs targeted at DNA topoisomerase II in the treatment of murine bladder cancer. J. Urol., 138, 427-429 (1987a).
2. ALEXANDER, R.B., NELSON, W.G. and COFFEY, D.S., Synergistic enhancement by tumor necrosis factor of in vitro cytotoxicity from chemotherapeutic drugs targeted at DNA topoisomerase II. Cancer Res., 47, 2403-2406 (1987b).
3. BAHNSON, R.R. and RATLIFF, T.L., In vitro and in vivo anti-tumor activity of recombinant mouse tumor necrosis factor (TNF) in a mouse bladder tumor (MBT-2). J. Urol , 144, 172-175 (1990).
4. BALOCH, Z., COHEN, S., FRESA, K. and COFFMAM, F.D., Modulation of topoisomerase activities by tumor necrosis factor. Cell. Immunol., 160, 98-103 (1995).
5. CHABNER, B.A. and MYERS, C.E., Clinical pharmacology of cancer chemotherapy. In: V.T. DeVita, Jr., S. Hellman and S.A. Rosenberg (eds.), Cancer - principles and practice of oncology (3rd ed.), pp. 349-395, J.B. Lippincott, Philadelphia (1989).
6. CREASEY, A.A., DOYLE, L.V., REYNOLDS, M.T., JUNG, T., LIN, L.S. and VITT, C.V., Biological effects of recombinant human tumor necrosis factor and its novel muteins on tumor and normal cell lines. Cancer Res., 47, 145-149 (1987).
7. DARZYNKIEWICZ, Z., CARTER, S.P. and OLD, L.J., Effect of recombinant tumor necrosis factor on HL-60 cells: cell-cycle specificity and synergism with actinomycin D.J. cell. Physiol , 130, 328-335 (1987).
8. EGGERMONT, A.M.M., LIÉNARD, D., SCHRAFFORDT KOOPS, H., ROSENKAIMER, F. and LEJEUNE, F.J., Treatment of irresectable soft tissue sarcomas of the limbs by isolation perfusion with high dose TNFα in combination with interferon-γ and melphalan. In: W. Fiers and W.A. Buurman (eds.), Tumor necrosis factor: molecular and cellular biology and clinical relevance, pp. 239-243, Karger, Basel (1993).
9. HIEBER, U. and HEIM, M.E., Tumor necrosis factor for the treatment of malignancies. Oncology, 51, 142-153 (1994).
10. KROSNICK, J.A., MULÉ, J.J., MCINTOSH, J.K. and ROSENBERG, S.A., Augmentation of antitumor efficacy by the combination of recombinant tumor necrosis factor and chemotherapeutic agents in vivo. Cancer Res., 49, 3729-3733 (1989).
11. LASER, W., WAŃKOWICZ, A., KUC, K., FELESZKO, W., GOLAB, J., GIERMASZ, A., WIKTOR-JEDRZEJCZAK, W. and JAKÓBISIAK, M., Potentiation of antitumor effects of tumor necrosis factor α and interferon γ by macrophage-colony-stimulating factor in a MmB16 melanoma model in mice. Cancer Immunol. Immunother., 40, 315-321 (1995).
12. NISHIMURA, T., OHTA, S., SATO, N., TOGASHI, Y., GOTO, M. and HASHIMOTO, Y., Combination tumor-immunotherapy with recombinant tumor necrosis factor and recombinant interleukin 2 in mice. Int. J. Cancer, 40, 255-261 (1987).
13. REGENASS, U., MÜLLER, M., CURSCHELLAS, E. and MATTER, A., Anti-tumor effects of tumor necrosis factor in combination with chemotherapeutic agents. Int. J Cancer, 39, 266-273 (1987).
14. SARRAF, C.E., Tumour necrosis factor and cell death in tumours. Int. J. Oncol., 5, 1333-1339 (1994).
15. SEIBEL, N.L., DINNDORF, P.A., BAUER, M., SONDEL, P.M., HAMMOND, G.D. and REAMAN, G.H., Phase I study of tumor necrosis factor-α and actinomycin D in pediatric patients with cancer: a children's cancer group study. J. Immunother., 16, 125-131 (1994).
16. SHIMOMURA, K., MANDA, T., MUKUMOTO, S., KOBAYASHI, K., NAKANO, K. and MORI, J., Recombinant human tumor necrosis factor-α: thrombus formation is a cause of anti-tumor activity. Int. J. Cancer, 41, 243-247 (1988).
17. SHOJI, Y., UEDONO, Y., ISHIKURA, H., TAKEYAMA, N. and TANAKA, T., DNA damage induced by tumor necrosis factor-α in L929 cells is mediated by mitochondrial oxygen radical formation. Immunology, 84, 543-548 (1995).
18. SIDHU, R.S. and BOLLON, A.P., Tumor necrosis factor activities and cancer therapy - a perspective. Pharmacol. Ther., 57, 79-128 (1993).
19. SRINIVASAN, J.M., FAJARDO, L.F. and HAHN, G.M., Mechanism of antitumor activity of tumor necrosis factor α with hyperthermia in a tumor necrosis factor α-resistant tumor. J. nat. Cancer Inst., 82, 1904-1910 (1990).
20. SUGARMAN, B.J., AGGARWAL, B.B., HASS, P.E., FIGARI, I.S., PALLADINO, JR., M.A. and SHEPARD, H.M., Recombinant human tumor necrosis factor-α: effects on proliferation of normal and transformed cells in vitro. Science, 230, 943-945 (1985).
21. UTSUGI, T., MATTERN, M.R., MIRABELLI, C.K. and HANNA, N., Potentiation of topoisomerase inhibitor-induced DNA strand breakage and cytotoxicity by tumor necrosis factor: enhancement of topoisomerase activity as a mechanism of potentiation. Cancer Res., 50, 2636-2640 (1990).
22. VOELKEL-JOHNSON, C., ENTINGH, A.J., WOLD, W.S.M., GOODING, L.R. and LASTER, S.M., Activation of intracellular proteases is an early event in TNF-induced apoptosis. J Immunol., 154, 1707-1716 (1995)
23. WASSERMANN, K., MARKOVITS, J., JAXEL, C., CAPRANICO, G., KOHN, K.W. and POMMIER, Y., Effects of morpholinyl doxorubicins, doxorubicin, and actinomycin D on mammalian DNA topoisomerases I and II. Mol. Pharmacol , 38, 38-45 (1990).
24. WHEELER, H R., ROCKETT, E.J., CLARK, I. and GECZY, C.L., Actinomycin D upregulates lipopolysaccharide induction of macrophage procoagulant expression and tumour necrosis factor-alpha production. Clin. exp. Med., 86, 304-310 (1991).
25. ZIEGLER-HEITBROCK, H.W.L., MOLLER, A., LINKE, R.P., HAAS, J.G., RIEBER, E.P. and RIETHMULLER, G., Tumor necrosis factor as effector molecule in monocyte mediated cytotoxicity. Cancer Res., 46, 5947-5952 (1986).